SCHEMBL1007071

SCHEMBL1007071

CCCCOC(=O)c1ccc(C(F)(F)F)nc1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
HSD17B10 Q99714 3/20 0.51
TSHR P16473 6/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
LMNA P02545 4/20 0.47
CYP3A4 P08684 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2C9 P11712 1/20 0.47
PDE4D Q08499 1/20 0.47
KDM4E B2RXH2 2/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 3/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ESR1 P03372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1375048 0.86 KDM4E (0.53) ALDH1A1HSD17B10TSHRL3MBTL1LMNA
SCHEMBL11179013 0.82 ALDH1A1 (0.55) ALDH1A1HSD17B10TSHRL3MBTL1TDP1
SCHEMBL27519990 0.81 ALDH1A1 (0.56) ALDH1A1HSD17B10TSHRL3MBTL1TDP1
SCHEMBL125591 0.79 TUBB4A (0.53) ALDH1A1HSD17B10LMNAPDE4DKDM4E
SCHEMBL27459666 0.75 ALDH1A1 (0.49) ALDH1A1HSD17B10TSHRL3MBTL1TDP1
SCHEMBL11169789 0.74 ALDH1A1 (0.55) ALDH1A1HSD17B10TSHRL3MBTL1TDP1
SCHEMBL5265221 0.73 ALDH1A1 (0.53) ALDH1A1HSD17B10TSHRL3MBTL1TDP1
SCHEMBL27487328 0.73 ALDH1A1 (0.50) ALDH1A1HSD17B10TSHRL3MBTL1TDP1
SCHEMBL2595579 0.72 ALDH1A1 (0.64) ALDH1A1HSD17B10TSHRL3MBTL1TDP1
SCHEMBL167782 0.72 KDM4E (0.47) ALDH1A1HSD17B10LMNACYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 ALDH1A1 614/4885HSD17B10 2980/4885TSHR 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.